SRR8943036
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- HEDGEHOG_SIGNALING+0.380
- IL6_JAK_STAT3_SIGNALING+0.360
- INFLAMMATORY_RESPONSE+0.350
- MYOGENESIS+0.350
- IL2_STAT5_SIGNALING+0.330
- KRAS_SIGNALING_DN+0.270
- COAGULATION+0.260
- KRAS_SIGNALING_UP+0.260
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.430
- MYC_TARGETS_V1-0.420
- PROTEIN_SECRETION-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.370
- P53_PATHWAY-0.350
- GLYCOLYSIS-0.330
- MTORC1_SIGNALING-0.310
- MYC_TARGETS_V2-0.300
- DNA_REPAIR-0.290
- FATTY_ACID_METABOLISM-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | aMVAC.P_004_TURBT_S222 | — | — | 0.882 |
| 2 | SRR13311178 | — | — | 0.877 |
| 3 | SRR33346956 | — | — | 0.872 |
| 4 | DRR168569 | — | — | 0.862 |
| 5 | GSM5359436 | — | — | 0.862 |
| 6 | ULC1711T_S63 | — | cohortA1 | 0.861 |
| 7 | 17d3d480-5503-419e-92cd-cbc7db9659d2 | — | — | 0.861 |
| 8 | DRR168582 | — | — | 0.858 |
| 9 | GSM5359446 | — | — | 0.856 |
| 10 | TCGA-98-A53H-01A-12R-A262-07 | — | cohortA1 | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |